Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing.

PloS One
Benjamin KrummelChristoph Lange

Abstract

Interferon (IFN)-gamma release assays (IGRA) have improved tuberculosis contact tracing, but discrimination of recent from remote Mycobacterium tuberculosis contacts is not possible by IGRA alone. We present results of a tuberculosis contact investigation with a new early-secretory-antigenic-target (ESAT)-6 and culture-filtrate-protein (CFP)-10 specific interleukin (IL)-2 ELISpot in addition to ESAT-6 and CFP-10 specific IFN-gamma ELISpot and tuberculin skin testing (TST). Results of the TST, IFN-gamma ELISpot and IL-2 ELISpot were positive in 6/172 (3.4%), 7/167 (4.2%) and 6/196 (3.1%) of contacts, respectively. Close contact (> or =100 hours) to the index case increased the risk of positive results in the IFN-gamma ELISpot, TST, and IL-2 ELISpot by 40.8, 19.3, and 2.5 times, respectively. Individuals with a positive IFN-gamma ELISpot/negative IL-2 ELISpot result had a median (IQR) duration of index case exposure of 568 hours (133_1000) compared to individuals with a positive IFN-gamma ELISpot/positive IL-2 ELISpot result (median = 24 hours; 20_130; p-value = 0.047). Combination of a M. tuberculosis specific IFN-gamma ELISpot with a M. tuberculosis specific IL-2 ELISpot significantly improved the identification of individuals ...Continue Reading

References

Sep 4, 1975·The New England Journal of Medicine·J E Sokal
Apr 11, 1996·The New England Journal of Medicine·T A KenyonK G Castro
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·N ReilingS Ehlers
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matthias EngeleSteffen Stenger
Feb 12, 2004·Arthritis and Rheumatism·Frederick WolfeKathy Urbansky
Mar 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maike BuettnerSteffen Stenger
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Holly M Scott AlgoodJoAnne L Flynn
Oct 22, 2005·Annals of the Rheumatic Diseases·S Stenger
Jul 22, 2006·American Journal of Respiratory and Critical Care Medicine·Claudia JafariChristoph Lange
Apr 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kerry A MillingtonAjit Lalvani
May 24, 2007·Pneumologie·R DielR Loddenkemper
Sep 20, 2008·PLoS Pathogens·Thierry WirthStefan Niemann
Jul 11, 2009·American Journal of Respiratory and Critical Care Medicine·Claudia JafariUNKNOWN Tuberculosis Network European Trialsgroup

❮ Previous
Next ❯

Citations

Jul 6, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S MamishiS Mahmoudi
Mar 29, 2011·Scandinavian Journal of Infectious Diseases·Ioannis K NeonakisEfthimia Petinaki
Oct 31, 2012·Respirology : Official Journal of the Asian Pacific Society of Respirology·Cynthia Bin-Eng CheeChristoph Lange
Jun 2, 2015·American Journal of Respiratory and Critical Care Medicine·Marc TebrueggeNigel Curtis
Oct 21, 2014·PLoS Neglected Tropical Diseases·S DhanasekaranUNKNOWN TB Trials Study Group
Apr 24, 2012·PloS One·Johannes NemethStefan Winkler
Jun 18, 2017·Frontiers in Cellular and Infection Microbiology·Ana V Ibarra-MenesesEugenia Carrillo

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PMA

Software Mentioned

Stata

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.